

Edgar Filing: VASOGEN INC - Form SC 13G

VASOGEN INC  
Form SC 13G  
July 09, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Vasogen Inc.

-----  
(Name of Issuer)

Common Shares, without par value

-----  
(Title of Class of Securities)

92232F 10 3

-----  
(CUSIP Number)

July 2, 2003

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

CUSIP No. 92232F 10 3

- 1) Names of Reporting Persons: Quest Diagnostics Incorporated  
I.R.S. Identification Nos. of Above Persons (entities only): 16-1387862
- 2) Check the Appropriate Box if a Member of a Group (See Instructions)

Edgar Filing: VASOGEN INC - Form SC 13G

(a)

(b)

3) SEC Use Only \_\_\_\_\_

4) Citizenship or Place of Organization: Delaware

---

Number of Shares	(5)	Sole Voting Power: 3,682,020
Beneficially Owned by		
Each Reporting Person	(6)	Shared Voting Power: 0
With		
	(7)	Sole Dispositive Power: 3,682,020
	(8)	Share Dispositive Power: 0

---

9) Aggregate Amount Beneficially Owned by Each Reporting Person: 3,682,020

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares  
(See Instructions)

11) Percent of Class Represented by Amount in Row 9: 5.9%

12) Type of Reporting Person (See Instruction): CO

Item 1(a) Name of Issuer: Vasogen Inc.

Item 1(b) Address of Issuer's Principal Executive Offices:  
2155 Dunwin Drive  
Mississauga, Ontario L5L 4M1  
Canada

Item 2(a) Name of Person Filing: Quest Diagnostics Incorporated

Item 2(b) Address of Principal Business Office or, if none, Residence:  
One Malcolm Avenue  
Teterboro, New Jersey 07608

Item 2(c) Citizenship: Delaware

Item 2(d) Title of Class of Securities: Common Shares without par value

Item 2(e) CUSIP Number: 92232F 10 3

Item 3. If this statement is filed pursuant to 'SS''SS' 240.13d-1(b) or  
240.13d-2(b) or (c), check whether the person filing is a:

(a)  Broker or dealer registered under section 15 of the  
Act (15 U.S.C 78o).

(b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C 78c).

## Edgar Filing: VASOGEN INC - Form SC 13G

- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C 78c).
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
- (e)  An investment adviser in accordance with 'SS' 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with 'SS' 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with 'SS' 240.13d-1(b)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with 'SS' 240.13d-1(b)(1)(ii)(J).

### Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 3,682,020 (including 625,237 shares that the reporting person has the right to acquire pursuant to a presently exercisable warrant issued by the issuer)

(b) Percent of class: 5.9% (including the issuance of 9.375 million common shares in the offering completed by the issuer on July 2, 2003 and including for purposes of this calculation the warrant referred to in Item 4(a))

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 3,682,020

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of:  
3,682,020

(iv) Shared power to dispose or to direct the disposition of: 0

### Item 5. Ownership of Five Percent or Less of a Class

Not applicable

### Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable

Edgar Filing: VASOGEN INC - Form SC 13G

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date July 9, 2003

s/ Leo C. Farrenkopf, Jr.

-----

Leo C. Farrenkopf, Jr.  
Vice President and Secretary

STATEMENT OF DIFFERENCES

The section symbol shall be expressed as ..... 'SS'